Anidulafungin: 3 agencies, 2008–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Treatment of invasive candidiasis in adult non-neutropenic patients”, while SMC (Scotland) recorded not recommended for “For the treatment of invasive candidiasis in adult non-neutropenic patients”.
The file has been open for more than a decade: 13.4 years separate the first record, 9 Jun 2008 at SMC (Scotland), from the most recent, 24 Nov 2021 at AWMSG (Wales).
SMC (Scotland) changed its position: not recommended on 9 Jun 2008, restricted by 10 Nov 2008, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for anidulafungin at all.
Nothing has been added since 2021; on this evidence the file is dormant.
SMC (Scotland) was first to assess anidulafungin, on 9 Jun 2008; HAS (France) did not open a file until 13 Jan 2010 — a moderate spread of 1.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
3 of the 3 agencies here assessed anidulafungin more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 3 of the 18 agencies here have assessed anidulafungin.
The full ledger for anidulafungin reads 5 recommended, 2 not recommended and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 24 Nov 2021 | Treatment of invasive candidiasis in paediatric patients aged 1 month to < 18 years | not endorsed (non-submission) | source |
| HAS (France) | 2 Jun 2021 | Indication extension | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 11 Jun 2009 | Treatment of invasive candidiasis in adult non-neutropenic patients | recommended (full) | source |
| SMC (Scotland) | 10 Nov 2008 | Invasive candidiasis in adult non-neutropenic patients | accepted (restricted) | source |
| SMC (Scotland) | 9 Jun 2008 | For the treatment of invasive candidiasis in adult non-neutropenic patients | not recommended | source |
3 further decisions for anidulafungin, across 1 agency, are not shown here.
Related molecules
- posaconazole — same ATC class J02A — Antimycotics
- voriconazole — same ATC class J02A — Antimycotics
- caspofungin — same ATC class J02A — Antimycotics
- isavuconazole — same ATC class J02A — Antimycotics
- micafungin — same ATC class J02A — Antimycotics
- cefazolin — also decided by AWMSG in 2021Q4
Coverage: 8 decisions for anidulafungin from 3 agencies, 2008 to 2021. Data to 7 Sep 2026. ATC class J02A — Antimycotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.